%0 Journal Article
%T Programming a serial killer: CAR T cells form non-classical immune synapses
%A Alexander J Davenport
%A Misty R Jenkins
%J Archive of "Oncoscience".
%D 2018
%R 10.18632/oncoscience.406
%X Chimeric Antigen Receptors (CARs) are engineered immune receptors that underpin a promising new form of cellular immunotherapy for the treatment of cancer. Recently there have been two landmark FDA approvals for the use of Chimeric Antigen Receptor (CAR) T cell therapy for B cell malignancies, and with more than 300 CAR T cell clinical trials globally, it has become more important than ever to investigate the cell biology of these new ˇ°livingˇ± immunotherapies. The rapid pace at which these therapies have been translated, means that we still have a way to go in understanding how triggering T cells via a synthetic engineered receptor might alter the cell biology, function and persistence of CAR T cells. We have previously shown that CAR T cells have the ability to be serial killers, a property likely to be a key requirement for effective anti-tumour therapy and ultimately influencing the numbers of CAR T cells required for effective therapy [1]
%K Immune synapse
%K T cells
%K Chimeric Antigen Receptor
%K Cytotoxicity
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978443/